• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

    49.44 +1.03 (+2.12%)
    Streaming Delayed Price Updated: 12:03 PM EDT, Jul 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,543,058
    Open 48.52
    Bid (Size) 49.39 (200)
    Ask (Size) 49.47 (200)
    Prev. Close 48.41
    Today's Range 47.74 - 50.01
    52wk Range 41.73 - 104.32
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Tempus AI Bets on MRD Testing Growth With Personalis Acquisition ↗
    Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma... 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
    From Tempus
    Via Business Wire

    Performance

    YTD
    -20.7%
    -20.7%
    1 Month
    +3.3%
    +3.3%
    3 Month
    -12.9%
    -12.9%
    6 Month
    -26.0%
    -26.0%
    1 Year
    -14.8%
    -14.8%

    More News

    Read More
    News headline image
    Tempus to Report Second Quarter 2026 Financial Results on July 30
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
    From Ambry Genetics
    Via Business Wire
    News headline image
    Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Why Tempus AI Stock Is Surging On Thursday? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    What to Know About This Fund's $32.6 Million Porch Group Purchase ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Why Is Tempus AI Stock Surging On Thursday? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
    From Tempus AI, Inc.
    Via Business Wire
    News headline image
    Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
    From Tempus AI, Inc.
    Via Business Wire
    TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
    Via Investor Brand Network
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Tempus AI, Inc. - Class A Common Stock publicly traded?
    Yes, Tempus AI, Inc. - Class A Common Stock is publicly traded.
    What exchange does Tempus AI, Inc. - Class A Common Stock trade on?
    Tempus AI, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tempus AI, Inc. - Class A Common Stock?
    The ticker symbol for Tempus AI, Inc. - Class A Common Stock is TEM on the Nasdaq Stock Market
    What is the current price of Tempus AI, Inc. - Class A Common Stock?
    The current price of Tempus AI, Inc. - Class A Common Stock is 49.44
    When was Tempus AI, Inc. - Class A Common Stock last traded?
    The last trade of Tempus AI, Inc. - Class A Common Stock was at 07/21/26 12:03 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.